Last Updated on December 31, 2023 by The Health Master
Lung cancer
Mirati Therapeutics, a frontrunner in the pharmaceutical industry, received encouraging news on Friday as the European Medicines Agency’s committee recommended the approval of its groundbreaking treatment for a specific type of lung cancer.
This marks a significant milestone for the company, especially considering the prior challenges faced in gaining authorization.
Background of Krazati:
Krazati, Mirati’s revolutionary drug, holds a pivotal role in combating a mutated form of the KRAS gene prevalent in approximately 13% of non-small cell lung cancers, the most common form of this disease.
Despite facing initial setbacks, Krazati obtained accelerated approval from the U.S. Food and Drug Administration last year and secured authorization from the UK health regulator earlier this month.
European Medicine Agency’s Committee Decision:
The journey to European approval was not without hurdles.
In July, the European Medicines Agency’s committee declined support for Krazati, citing unmet requirements for conditional approval.
Mirati, however, contested this decision, asserting the drug’s efficacy and meeting the necessary criteria.
Re-examination of Krazati:
A re-examination process ensued, and the committee revisited its decision.
Factors contributing to this reversal were thoroughly assessed, emphasizing the importance of conditional support for drugs with transformative potential.
The turnaround highlights the committee’s commitment to patient welfare and staying abreast of evolving medical landscapes.
Krazati’s Global Approvals:
While the European approval is a significant achievement, it builds upon Krazati’s previous successes.
The drug’s acceptance in the U.S. and the UK underscores its global impact and showcases Mirati’s commitment to providing cutting-edge solutions to a broader patient population.
Targeting KRAS Mutation:
Understanding Krazati’s mechanism is crucial. The drug is designed to specifically target the mutated KRAS gene found in non-small cell lung cancers.
As this mutation is present in a substantial portion of cases, Krazati holds promise as a targeted and effective treatment.
Bristol Myers Squibb’s Acquisition:
In a strategic move, Bristol Myers Squibb recently agreed to acquire Mirati for up to $5.8 billion.
This acquisition aims to diversify Bristol Myers Squibb’s oncology business, solidifying Krazati’s role as a cornerstone in the company’s expanding portfolio.
Krazati’s Role in Oncology:
Krazati’s significance extends beyond its immediate impact on lung cancer treatment.
Its role in advancing oncology, especially in targeting specific genetic mutations, positions it as a beacon of hope in the evolving landscape of cancer therapies.
A recent setback for a rival drug, Lumakras, further underscores Krazati’s importance in the field.
Krazati’s Return to Spotlight:
Recent events have thrust Krazati back into the spotlight.
The U.S. FDA’s advisers’ decision to withhold support for Lumakras, citing concerns about trial data reliability, highlights the critical need for robust and effective treatments like Krazati.
FAQs:
- What is the significance of Krazati’s approval in Europe?
- Krazati’s approval in Europe signifies a crucial step in expanding its global impact and providing patients with an innovative treatment option.
- How does Krazati target the mutated KRAS gene?
- Krazati is designed to specifically target the mutated form of the KRAS gene, which is prevalent in about 13% of non-small cell lung cancers.
- Why did the European Medicines Agency’s committee initially decline support for Krazati?
- The committee initially declined support for Krazati in July, citing unmet requirements for conditional approval, which Mirati contested.
- What is the significance of Bristol Myers Squibb’s acquisition of Mirati?
- Bristol Myers Squibb’s acquisition of Mirati for up to $5.8 billion aims to diversify its oncology business, with Krazati playing a key role.
- How does Krazati compare to rival drug Lumakras?
- Krazati’s recent spotlight comes in the wake of Lumakras facing setbacks from the U.S. FDA’s advisers, highlighting the importance of effective and reliable treatments.
Torrent and Zydus Join Forces to Combat Liver Disorders
17 Crore: Most costly Lifeline injection for SMA Afflicted Children
USFDA issues EIR For Piramal Pharma Bethlehem Facility
Drug recall: These Eye Drops recalled due to Potential Risk of Eye Infections
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
